High expression of MORC2 predicts worse neoadjuvant chemotherapy efficacy in triple negative breast cancer
Open Access
- 23 June 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (25) , e34164
Abstract
Tumor infiltrating lymphocytes (TILs) are closely related to the patients’ prognosis. Recently, Microrchidia 2 (MORC2) has been documented as a prognostic and predictive biomarker in triple negative breast cancer (TNBC). To compare whether MORC2 is a better predictor than TILs, as well as clinicopathological parameters, in predicting the efficacy of neoadjuvant chemotherapy (NAC) in TNBC, we detected the expression of MORC2 on neoplastic cells through immunohistochemistry and quantified the stromal TILs through Hematoxylin-eosin staining on core biopsies from 50 locally advanced TNBC patients who underwent standard NAC. Among all the 50 patients, 28 (56%) cases had residual tumors, while the other 22 (44%) achieved pathologic complete response (pCR). In these studied patients, age and T-stage showed no correlation with pCR rate, while percentage of TILs, nodal involvement and expression of MORC2 on tumor cells showed significant association with pCR rate. Positive nodal involvement was correlation with worse pathologic response at multivariate analysis (P = .0036), and high TILs levels (≥50%) was positively associated with better NAC efficacy at univariate analysis (P = .002). Whereas high expression of MORC2 was statistically associated with worse pCR rate both at univariate (P < .001) and multivariate (P = .036) analysis. Our results indicate that MORC2 expression has a better predictive role in predicting the efficacy of NAC than TILs in TNBC patients.Keywords
This publication has 33 references indexed in Scilit:
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapyThe Lancet Oncology, 2018
- Immune Gene Expression Is Associated with Genomic Aberrations in Breast CancerCancer Research, 2017
- Tumor microenvironment and therapeutic responseCancer Letters, 2017
- Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer SubtypesJAMA Oncology, 2016
- Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working groupLaboratory Investigation, 2015
- Macroscopic handling and reporting of breast cancer specimens pre‐ and post‐neoadjuvant chemotherapy treatment: review of pathological issues and suggested approachesHistopathology, 2015
- Role of inflammatory infiltrates in triple negative breast cancerJournal of Clinical Pathology, 2015
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014Annals of Oncology, 2014
- Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer NetworkCancer, 2012
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991